ABSTRACT Objectives This study aimed to evaluate the effects of anti‐resorptive drugs (ARD), including denosumab, on dental implant survival in post‐menopausal women with osteoporosis, compared with those receiving non‐ARD, and to identify risk factors associated with ARD that may influence implant outcomes. Material and Methods This retrospective cohort study examined 1694 implants placed in 806 women aged 55 years or older with at least of follow‐up of 12 months. Implants were categorized according to exposure to anti‐resorptive drugs (ARD), including bisphosphonates or denosumab, or assignment to a non‐ARD control group. The assessed variables included demographic, ARD‐related, implant/prosthesis‐related factors, and marginal bone loss. Propensity score matching was used to balance group characteristics. Statistical analyses included Firth logistic regression with patient‐level clustering and a linear mixed model for longitudinal bone changes. Kaplan–Meier curves were illustrated to describe implant survival trends among the groups. Results Implant survival rates were 99.13% (bisphosphonates), 98.08% (denosumab), and 98.24% (control), with no significant differences in implant failure or marginal bone loss between the groups. However, diabetes mellitus, alcohol consumption, and overdenture prosthesis were associated with a significantly increased risk of implant failure. Conclusion Implant‐based prosthetic rehabilitation is also feasible in post‐menopausal women receiving ARD for osteoporosis. Although the implant survival rate was comparable to non‐ARD users, caution is advised for patients on high doses of ARD or undergoing long‐term therapy due to their pharmacological effects compromising bone metabolism. Additionally, the risk of failure associated with invasive procedures needs to be further evaluated.
Hwang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: